Eyes On Imprimis...

(RTTNews) - Shares of Imprimis Pharmaceuticals Inc. (IMMY) have returned more than 110% year-to-date while the iShares Nasdaq Biotechnology ETF (IBB) has fallen 4% during the same period.

Imprimis is a commercial-stage pharmaceutical company. Besides owning ImprimisRx, an ophthalmology pharmaceutical compounding business, Imprimis also has a stake in Eton Pharmaceuticals, Surface Pharmaceuticals and Melt Pharmaceuticals.

Eton Pharmaceuticals, in which Imprimis has about 27% passive stake, is expected to make its debut on the NASDAQ on October 30. In Surface Pharmaceuticals, Imprimis has roughly 30% passive equity stake.

The Company began generating revenue beginning on April 1, 2014, when it acquired its first ImprimisRx compounding pharmacy.

Over the years, Imprimis' total revenue has grown significantly.

In the first half ended June 30, 2018, the Company's net loss narrowed to $991 thousand or $0.05 per share on revenue of $19.2 million. This compared with a net loss of $3.52 million or $0.18 per share and revenue of $12.95 million in the year-ago period.

The Company ended June 30, 2018, with cash of $4.17 million.

Imprimis has set itself a target of generating $100 million in revenue in 2021.

Shares of Imprimis made their debut on the NASDAQ on April 30, 2007. (Source: crunchbase). Two reverse splits - a 1 for 8 reverse split on February 24, 2012 and a 1 for 5 reverse split on February 08, 2013 - have been implemented.

In the last 1 year, IMMY has traded in a range of $1.35 to $4.05. The stock closed Wednesday's trading at $3.63, down 4.22%.